Epkinly plus R-CHOP shows a strong PFS benefit in first-line DLBCL on October 21, 2026 AbbVie Diffuse Large B-Cell Lymphoma DLBCL-2 EPCORE Epcoritamab Epkinly Genmab PFS R-CHOP Regimen +
Epkinly posts a first-line DLBCL trial win—but “best” remains unproven on October 07, 2026 AbbVie Diffuse Large B-Cell Lymphoma DLBCL-2 EPCORE Epcoritamab Epkinly first-line Genmab Polivy R-CHOP Regimen +